Salbutamol
Salbutamol has been studied in 5 papers since 2024: 2 observational studies in people, 2 in animals, 1 in cells; 4 in the past year. The newest paper, Jun 12, 2026: “Retrospective case-control study of pre-diagnosis observational and prescription data in Parkinson's disease”.
See all 8 papers on salbutamol
At a glance
The findings reach people, from one lab or study. 2 independent labs in 2 countries; 11 trials, none about aging, 2 with no results posted.
“Previously reported contrasting associations of salbutamol and propranolol with Parkinson's disease incidence were confirmed.”
None of its findings points the other way.
- 2 independent labs in 2 countries
- 11 trials, none about aging, 2 with no results posted
- Funders: Hebei Natural Science Foundation and 2 more
- Humans2
- Animals2
- Cells1
What did studies of salbutamol find?
2Studies of salbutamol measured 2 outcomes; the most studied are cell arrhythmias (1 study) and QTc (1).
Cell arrhythmias
upin human cells1
1 study
Cell arrhythmias
upin human cells1
Salbutamol induces cell arrhythmias in human cells (D-galactose-induced aging).
“In D-galactose-induced aging hiPSC-CMs, SAL-induced repolarization delay and cell arrhythmias, consistent with findings in aging hearts.”
CellsD-galactose-induced aginghuman-induced pluripotent stem cell-derived cardiomyocyte
Scientific reports
QTc
downin C. porcellus1
1 study
QTc
downin C. porcellus1
Salbutamol decreases QTc in C. porcellus.
“β2AR agonist salbutamol (SAL) shortened QTc in a concentration-dependent manner in young hearts”
Animalsheart
Scientific reports
What is salbutamol linked with?
1Studies link salbutamol with 1 measure, most often Parkinson's disease incidence (1 study).
Parkinson's disease incidence
mixedin humans1
1 study
Parkinson's disease incidence
mixedin humans1
Salbutamol is associated with Parkinson's disease incidence in humans (replication of earlier reported association).
“Previously reported contrasting associations of salbutamol and propranolol with Parkinson's disease incidence were confirmed.”
Humansreplication of earlier reported association
Scientific reports
Trial sponsors
Company3 trialsPhase 32,888 people
Company2 trialsPhase 3279 people
Company1 trialPhase 31,025 people
Company1 trialPhase 3787 people
Company1 trialPhase 3310 people
Company1 trialPhase 2140 people
Company1 trialPhase 246 people
China National Center for Cardiovascular Diseases
1 trial390 people